- Home
- PDM vs OPK Comparison
PDM vs OPK Comparison
Compare PDM & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | OPK |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.8M | 921.2M |
| IPO Year | 1997 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PDM | OPK |
|---|---|---|
| Price | $7.65 | $1.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $9.00 | $1.55 |
| AVG Volume (30 Days) | 998.7K | ★ 2.4M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $564,994,000.00 | ★ $606,879,000.00 |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | $1.57 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.46 | $1.10 |
| 52 Week High | $9.19 | $1.60 |
Technical Indicators
Market Signals| Indicator | PDM | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 57.91 |
| Support Level | $7.55 | $1.12 |
| Resistance Level | $7.83 | $1.25 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 91.64 | 96.00 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.